EC21
EC21 is a PROTAC degrader that binds to CDK6, thereby targeting EYA2 for degradation. EC21 enhances the interaction between CDK6 and EYA2, thereby driving ubiquitin-proteasome-dependent degradation of EYA2. EC21 reduces EYA2 protein levels in tumor tissues without obvious toxicity. EC21 disrupts the DNA damage repair pathway and inhibits cancer cell proliferation. EC21 can be used in breast cancer-related research.
(Pink: EYA2 ligand (HY-184746); Blue: CDK6 ligand (HY-50767); Black: linker).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C53H60N10O11
- Molecular Weight:1013.10
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle PROTACs Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CDK6 |
EYA2 |
In Vitro
EC21 (72 h) potently inhibits the proliferation of MDA-MB-231 and 4T1 triple-negative breast cancer cells, with IC50 values of 7.84 μM and 6.56 μM, respectively, after 72 h of treatment[1].
EC21 (10 μM; 0-24 h) induces time-dependent degradation of EYA2 protein in MDA-MB-231 and 4T1 triple-negative breast cancer cells (following treatment with 10 μM for up to 24 h)[1].
EC21 (5-20 μM; 24 h) induces concentration-dependent degradation of EYA2 protein in MDA-MB-231 and 4T1 triple-negative breast cancer cells[1].
EC21 (10 μM EC21 + 100 μg/mL Cycloheximide (HY-12320); 12 h) accelerates the degradation of pre-existing EYA2 protein in MDA-MB-231 and 4T1 triple-negative breast cancer cells[1].
EC21 (10 μM EC21; 4 h co-incubation following 2 h pre-treatment with 10 μM MG132 (HY-13259)) induces EYA2 degradation in MDA-MB-231 and 4T1 triple-negative breast cancer cells, and this process is dependent on the ubiquitin-proteasome system[1].
EC21 (10 μM; 6 h) enhances the physical interaction between endogenous CDK6 and EYA2 in MDA-MB-231 and 4T1 triple-negative breast cancer cells in a reciprocal co-immunoprecipitation assay[1].
EC21 (10 μM; 6 h) increases the colocalization level of CDK6 and EYA2 in MDA-MB-231 and 4T1 triple-negative breast cancer cells, with Pearson correlation coefficients of 0.680 and 0.699, respectively[1].
EC21 (10 μM; 24 h) inhibits the migration of MDA-MB-231 and 4T1 triple-negative breast cancer cells[1].
EC21 (10 μM; 14 days) potently inhibits the clonogenic capacity of MDA-MB-231 and 4T1 triple-negative breast cancer cells[1].
Treatment with EC21 (10 μM; 24 h) induces apoptosis in MDA-MB-231 and 4T1 triple-negative breast cancer cells, and the total apoptosis rate is higher than that of the control group[1].
EC21 (10 μM; 24 h) induces G1 phase arrest and impairs G1/S cell cycle transition in MDA-MB-231 and 4T1 triple-negative breast cancer cells when treated at 10 μM for 24 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:0, 6, 12, 24 h
-
Result:Induced a time-dependent reduction in EYA2 protein levels in both cell lines.
Caused significant decreases observed at 12 h and 24 h compared to the 0 h control.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Induced a concentration-dependent reduction in EYA2 protein levels in both cell lines.
Caused significant decreases observed at all tested concentrations compared to the 0 μM control.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM, 100 μg/mL CHX
-
Incubation Time:12 h
-
Result:Resulted in markedly lower EYA2 protein levels in cells co-treated with EC21 and CHX compared to cells treated with CHX alone.
Indicated acceleration of degradation of pre-existing EYA2 protein.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM,10 μM MG132
-
Incubation Time:2 h (MG132 pre-incubation); 4 h ( co-incubation)
-
Result:Pre-treatment with MG132 effectively rescued the EC21-induced reduction in EYA2 protein levels.
Confirmed proteasome involvement in EYA2 degradation.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:6 h
-
Result:Markedly enhanced the association of endogenous EYA2 with CDK6 in both cell lines compared to untreated controls.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:2 h (pre-treatment with single-target inhibitors); 24 h (EC21 co-incubation)
-
Result:Pre-incubation with either palbociclib or ETC-616 significantly attenuated EC21-induced EYA2 degradation in both cell lines.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:6 h; 4 h co-incubation after 2 h pre-treatment with single-target inhibitors
-
Result:Significantly increased intracellular co-localization of CDK6 and EYA2, raising the Pearson correlation coefficient to 0.680 in MDA-MB-231 and 0.699 in 4T1 cells.
Had enhanced co-localization blocked by pre-treatment with palbociclib or ETC-616.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Markedly suppressed wound closure in both cell lines at 24 h compared to control treatments.
Indicated reduced cell migration.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:14 days
-
Result:Resulted in the lowest number of surviving colonies compared to control treatments.
Indicated stronger inhibition of clonogenic growth.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Induced a higher rate of total apoptosis (early + late apoptotic cells) compared to control treatments in both cell lines.
-
Cell Line:MDA-MB-231, 4T1 triple-negative breast cancer cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Induced pronounced G1-phase arrest in both cell lines.
Impaired the G1/S transition more effectively than control treatments.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-8 weeks old, 18-22 g, subcutaneous 4T1 murine mammary carcinoma cell implantation)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:i.p.; every two days; 21 days
-
Result:Dose-dependently inhibited tumor growth and reduced tumor weight and intratumoral EYA2.
Decreased Ki67 and increased γ-H2AX.
No significant body-weight loss or major-organ pathology was observed at 10 mg/kg; 30 mg/kg caused a nonsignificant downward trend in body weight.
Chemical Information
-
Molecular Weight 1013.10
-
Formel C53H60N10O11
-
SMILES
O=C(C1=CC(OC2=CC=CC=C2)=CC=C1)N/N=C/C(O3)=CC=C3C(NCCOCCOCCOCCOCC(N(CC4)CCN4C(C=N5)=CC=C5NC(N=C6N7C8CCCC8)=NC=C6C(C)=C(C(C)=O)C7=O)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)